,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny 04', 'bcsm']
destiny 04 got a standing ovation, which was why we were thrilled that interviewed for #obroncology! stay tuned for amazing peer to peer insights! #asco22 #bcsm 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.